
Product Data Sheet

Product Name: 4-(n-nonyl) Benzenboronic Acid

Cat. No.: GC17159

Chemical Properties

Cas. No. 256383-45-6

Chemical Name B-(4-nonylphenyl)-boronic acid

SMILES CCCCCCCCC1=CC=C(B(O)O)C=C1

Formula $C_{15}H_{25}BO_2$ M.Wt 248.2

Solubility $\geq 11.75\text{mg/mL}$ in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

IC50: 9.1 nM

4-(n-nonyl) Benzenboronic acid is a dual FAAH inhibitor.

Fatty acid amide hydrolase (FAAH), a membrane-bound enzyme of the endocannabinoid system, has been identified as a potential target for therapeutic agents in the treatment of various medical conditions, such as inflammation and pain. FAAH and monoglyceride lipase (MGL) have been reported to be the primary enzyme responsible for the hydrolysis of endocannabinoid N-arachidonoyl ethanolamide (AEA), which is a key lipid messenger in the brain and periphery.

In vitro: 4-(n-Nonyl) benzenboronic acid was synthesized as a potent inhibitor of FAAH, with an IC50 of 9.1 nM. 4-(n-Nonyl) benzenboronic acid was also found to be able to inhibit MAGL, which could hydrolyze 2-arachidonoyl glycerol, but at around 1000-fold higher concentration. Moreover, it was found that as the most potent para-substituted

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

compound, 4-(n-Nonyl) benzenboronic acid showed rather high pKa of 9.1. In addition, the molecular docking was utilized to gain insight on the FAAH binding mode of 4-(n-Nonyl) benzenboronic acid and a putative binding mode was observed [1].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

Reference:

[1] Minkkil, A. ,Saario, S.M.,Ksnnen, H., et al. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. Journal of Medicinal Chemistry 51, 7057-7060 (2008).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA